Major honors, prizes, and institutional achievements.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
This Technion antisemitism panel discusses it persisting in U.S. academia for decades, calling for open dialogue and institutional change to combat this crisis.
As part of its centennial Board of Governors meeting, Technion confers honorary doctorates in a celebratory ceremony, honoring leaders who’ve significantly contributed to science and society.
Technion awards the 2025 Harvey Prize to three trailblazing scientists in cancer epigenetics, recognising their transformative work in advancing cancer diagnosis and treatment.
The Technion received the 2025 Defense Minister’s Shield of Appreciation for its outstanding support of student reservists during the Swords of Iron War.
Technion has named the 2023 Harvey Prize recipients, honoring groundbreaking work in mRNA vaccines and theoretical physics.
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla for extraordinary achievement in developing a vaccine for COVID-19 The President of the Technion – Israel Institute of Technology, Professor Uri Sivan announced that the Technion will award an honorary doctorate to Pfizer CEO
A Technion Innovation to capture COVID-19 viral particles with an active sanitization gel A Technion student team recently won a gold medal in the iGEM international synthetic biology competition for work developing an active gel to capture SARS-CoV-2 viral particles, preventing the infection of host
Technion Assistant Professor Daniel Soudry joins Intel’s Rising Star Faculty award program Intel’s Rising Star Faculty Award program selected 10 university faculty members who show great promise in developing future computing technologies. From projects such as a novel cloud system stack, to ultra-low power computing
Three scientists who received Technion’s Harvey Prize will be awarded a Nobel Prize in 2020 Technion Harvey Prize as a predictor of the Nobel. In early October 2020, the Nobel Prize Committee announced the winners for this year’s prestigious international prize. Three of the new
